MDimune

BUSINESS

INNOVATIVE THERAPIES BASED ON A NEXT-GENERATION DRUG DELIVERY PLATFORM

At MDimune, we are passionate about changing the world by developing innovative therapeutics.

Developing targeted drug delivery to cancer cells using vesicles loaded with cytotoxic agents in vitro and in vivo analyses/preclinical studies for various anticancer drugs underway.
Developing autologous cancer therapeutics by administering anticancer drugs loaded in the vesicles that are derived from leukocytes isolated from cancer patients
Versatile technology to carry various molecular cargos (siRNAs/miRNAs, proteins/peptides, small molecules, etc.)

Developing a platform technology using adult stem cell-derived vesicles exhibiting anti-inflammatory and regenerative properties to treat various diseases
Improving synergistic effects by combining regenerative potentials of adult stem cell-derived vesicles with known efficacies of various drugs loaded in the vesicles
Developing therapeutics to treat incurable diseases such as osteoarthritis, COPD, neurodegenerative diseases, etc

Providing vesicles derived from immune cells or stem cells to pharmaceutical companies to promote the development of novel therapeutics
Providing customized services by producing vesicles from cell types of interest to facilitate the R&D efforts of pharmaceutical companies

MDimune Inc. is partnering with world-renowned drug development experts to achieve global success.

Collaboration

Building a professional network with universities, research institutes, and pharmaceutical companies
Global marketing

Seeking marketing partners for the global application of technology and licensing
Clinical trial

Building a clinical trials network with major hospitals in Korea